Compare Ascendis Pharma A/S (ASND) vs Walmart Stores Inc (WMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Walmart Stores Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Walmart Stores Inc trades at $114.17 (market cap $906.43B). The key difference: Walmart Stores Inc is far larger — about 51.1× Ascendis Pharma A/S's market cap, and Walmart Stores Inc pays a 0.87% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WMT | |
|---|---|---|
Market Cap | $17.74B | $906.43B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $134.20 |
52-Week Low | $163.32 | $94.40 |
Enterprise Value | $18.11B | $969.88B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Walmart (WMT) trades at $113.9, up 1.51% today, amid mixed signals. The stock shows bearish technical indicators but strong fundamentals with consistent earnings beats and revenue growth to $681.0 billion in 2025. Recent news highlights Walmart's AI initiatives and philanthropic efforts, while competition intensifies as Amazon surpasses it in Fortune 500 revenue ranking.
The outlook remains positive with a consensus price target of $141.64, implying significant upside. Risks include competitive pressures and economic sensitivity, but Walmart's scale, dividend stability, and operational efficiency support a bullish long-term view for investors seeking defensive growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
